Polymorphs of a mPGES-1 inhibiting triazolone compound
The present application relates to solid state forms of a triazolone compound which exhibit mPGES-1 enzyme inhibition activity, specifically N-(4-chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)benzyl) pivalamide (Compound of formula II), and process for preparation thereof.
1. A crystalline form of N-(4-chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)benzyl)pivalamide (Compound formula II), structurally represented as
2. The crystalline form according to claim 1 , having a characteristic X-ray diffraction pattern comprising of the peaks expressed in terms of 2θ±0.2: 5.66, 6.55 and 13.05.
3. The crystalline form according to claim 1 , having a characteristic X-ray diffraction pattern comprising of the peaks expressed in terms of 2θ±0.2: 5.66, 6.55, 12.51, 13.05, 15.01, 16.59 and 25.69.
4. The crystalline form according to claim 1 , having a characteristic X-ray diffraction pattern comprising of the following peaks expressed in terms of 2θ±0.2: 24.57 and 30.85.
5. The crystalline form according to claim 1 , having a characteristic X-ray diffraction pattern comprising of the following peaks expressed in terms of 2θ±0.2: 7.02, 12.54, 16.64, 18.31, 24.57, 25.74 and 30.85.
6. The crystalline form according to claim 1 , having a characteristic X-ray diffraction pattern comprising of the following peaks expressed in terms of 2θ±0.2: 13.92, 31.01, 35.13 and 38.54.
7. The crystalline form according to claim 1 , having a characteristic X-ray diffraction pattern comprising of the following peaks expressed in terms of 2θ±0.2: 7.00, 12.60, 13.92, 16.71, 20.89, 24.55, 31.01, 35.13 and 38.54.
8. The crystalline compound of formula (II) according to claim 1 , having an average particle size value (D 50 ) in the range from about 1 μm to about 100 μm.
9. An amorphous form of N-(4-chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)benzyl) pivalamide.
10. A process for preparation of crystalline form of N-(4-chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)benzyl)pivalamide, having a characteristic X-ray diffraction pattern comprising of the peaks expressed in terms of 2θ±0.2: 5.66, 6.55, and 13.05, which process comprises the following steps:
a) taking N-(4-chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)benzyl)pivalamide in a mixture of diethyl ether and methanol or in a mixture of methyl tert-butyl ether and methanol;
b) stirring the mixture of step (a); and
c) isolating the desired compound.